Table 1.
Baseline characteristics of TNBC patients included in this study (N = 790).
| Characteristics | WCH cohort (n = 608) | TCGA cohort (n = 182) | P value (Chi-square) |
|---|---|---|---|
| histopathology image slides | 1,199 | 218 | |
| histopathology image tiles | 21,927 | 3,260 | |
| Age | < 0.001 | ||
| ≤40 | 140 (23.03%) | 17 (9.34%) | |
| 41–50 | 222 (36.51%) | 51 (28.02%) | |
| 51–60 | 164 (26.97%) | 45 (24.73%) | |
| >60 | 82 (13.49%) | 69 (37.91%) | |
| Menopause | < 0.001 | ||
| No | 335 (55.10%) | 45 (24.72%) | |
| Yes | 273 (44.90%) | 113 (62.09%) | |
| Unavailable | 0 (0.00%) | 24 (13.19%) | |
| Ki-67 | |||
| ≤20% | 91 (14.97%) | – | |
| >20% | 505 (83.06%) | – | |
| Unavailable | 12 (1.97%) | – | |
| Grade | |||
| II | 59 (9.70%) | – | |
| III | 395 (64.97%) | – | |
| Unavailable | 154 (25.33%) | – | |
| T stage | 0.006 | ||
| T1 | 180 (29.60%) | 47 (25.82%) | |
| T2 | 331 (54.44%) | 112 (61.54%) | |
| T3 | 33 (5.43%) | 15 (8.24%) | |
| T4 | 28 (4.61%) | 8 (4.40%) | |
| Unavailable | 36 (5.92%) | 0 (0.00%) | |
| N stage | 0.285 | ||
| N0 | 347 (57.07%) | 108 (59.34%) | |
| N1 | 154 (25.33%) | 47 (25.82%) | |
| N2 | 48 (7.90%) | 18 (9.89%) | |
| N3 | 54 (8.88%) | 9 (4.95%) | |
| Unavailable | 5 (0.82%) | 0 (0.00%) | |
| NACT | < 0.001 | ||
| No | 505 (83.06%) | 182 (100.00%) | |
| Yes | 103 (16.94%) | 0 (0.00%) | |
| ACT | < 0.001 | ||
| No | 7 (1.15%) | 108 (59.34%) | |
| Yes | 601 (98.85%) | 74 (40.66%) | |
| PMRT | < 0.001 | ||
| No | 396 (65.13%) | 91 (50.00%) | |
| Yes | 212 (34.87%) | 91 (50.00%) | |
| LVI | |||
| No | 428 (70.39%) | – | |
| Yes | 37 (6.09%) | – | |
| Unavailable | 143 (23.52%) | – | |
| BCS | < 0.001 | ||
| No | 554 (91.12%) | 133 (73.08%) | |
| Yes | 54 (8.88%) | 49 (26.92%) | |
*NACT neoadjuvant chemotherapy, ACT adjuvant chemotherapy, PMRT postmastectomy radiotherapy, LVI lymphovascular invasion, BCS breast-conserving surgery.